ELF4 and cancer: The frequency of somatic mutations increases with age in both non-cancerous and cancer tissue [39–42]; therefore we suggest that the link between the expression of ELF4 and the mutation burden could be exploited to establish therapeutics that are more effective in treating specific cancers.